• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Eyenovia Inc.

    11/14/24 5:08:44 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EYEN alert in real time by email
    SC 13G/A 1 armistice-eyen093024a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    EYENOVIA, INC.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    30234E104

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  30234E104
     SCHEDULE 13G/A
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Armistice Capital, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    8,600,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    8,600,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    8,600,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.95%
    12
    TYPE OF REPORTING PERSON
     
    IA, OO

     


     

    CUSIP No.  30234E104
     SCHEDULE 13G/A
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Steven Boyd
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    8,600,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    8,600,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    8,600,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.95%
    12
    TYPE OF REPORTING PERSON
     
    IN, HC

     


     

     

    CUSIP No. 30234E104
     SCHEDULE 13G/A
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    EYENOVIA, INC.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    3710 - 33rd Street

    NW Calgary, Alberta

    Canada, T2L 2MI

    Item 2.(a) Names of Person Filing:

    Armistice Capital, LLC

    Steven Boyd

    Collectively, the "Reporting Persons"

      

    Item 2.(b) Address of Principal Business Office:

     

    Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     

    Steven Boyd

    c/o Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

      

    Item 2.(c) Citizenship:

     

    Armistice Capital, LLC - Delaware

    Steven Boyd - United States of America

      

    Item 2.(d) Title of Class of Securities

     

    Common Stock, par value $0.0001 per share (“Shares”)

     

    Item 2.(e) CUSIP No.:

    30234E104

     

    CUSIP No.  30234E104
     SCHEDULE 13G/A
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 30234E104
     SCHEDULE 13G/A
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned as of September 27, 2024:

    Armistice Capital, LLC - 8,600,000

    Steven Boyd - 8,600,000   

    (b) Percent of Class as of September 27, 2024:

    Armistice Capital, LLC - 9.95%

    Steven Boyd - 9.95% 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (ii) Shared power to vote or to direct the vote

    Armistice Capital, LLC - 8,600,000

    Steven Boyd - 8,600,000  

    (iii) Sole power to dispose or to direct the disposition of

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (iv) Shared power to dispose or to direct the disposition of

    Armistice Capital, LLC - 8,600,000

    Steven Boyd - 8,600,000

    The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on information from the Issuer.

    Armistice Capital, LLC (“Armistice Capital”) is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

     

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 30234E104
     SCHEDULE 13G/A
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

           

     

     
    CUSIP No. 30234E104
     SCHEDULE 13G/A
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: November 14, 2024

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           
     

     
      By:  /s/ Steven Boyd
       

    Steven Boyd

           
    Get the next $EYEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EYEN

    DatePrice TargetRatingAnalyst
    11/18/2024$12.00 → $2.00Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $EYEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Eyenovia Provides Development Update on Optejet User Filled Device (UFD)

      NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today provided an update on recent progress made in the development of the Company's novel Optejet UFD. The user-filled Optejet is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products, spanning multiple billion-dollar markets. Eyenovia continues to advance the Optejet UFD through Verification & Validation (V&V) studies to ensure that the device meets the st

      4/10/25 7:00:00 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq

      Combination, if successful, would create a new publicly-listed eye care company combining Betaliq's EyeSol® water-free drug delivery technology for glaucoma with Eyenovia's Optejet® device platform The combined company would continue marketing Eyenovia's FDA-approved products – and plans to in-license additional products to generate near-term revenue NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has entered into a non-binding letter of inten

      3/20/25 7:00:00 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements

      NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announced that it has been informed by staff of The Nasdaq Stock Market LLC that the Company has regained compliance with all Nasdaq Capital Market continued listing requirements, including Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement rule, and Listing Rule 5810(c)(3)(A)(iii), the low priced stocks rule. "Maintaining our Nasdaq listing, along with other steps we have taken to restructure the company and accelerate development of the user-filled Optejet, repre

      2/26/25 7:00:00 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EYEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Eyenovia downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded Eyenovia from Buy to Neutral and set a new price target of $2.00 from $12.00 previously

      11/18/24 7:44:30 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Eyenovia with a new price target

      HC Wainwright & Co. reiterated coverage of Eyenovia with a rating of Buy and set a new price target of $8.00 from $6.00 previously

      4/1/21 6:45:58 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Northland Capital initiated coverage on Eyenovia with a new price target

      Northland Capital initiated coverage of Eyenovia with a rating of Outperform and set a new price target of $10.00

      3/1/21 9:11:48 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EYEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $EYEN
    SEC Filings

    See more
    • Amendment: SEC Form SC 13D/A filed by Eyenovia Inc.

      SC 13D/A - EYENOVIA, INC. (0001682639) (Subject)

      12/4/24 4:12:20 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Eyenovia Inc.

      SC 13G/A - EYENOVIA, INC. (0001682639) (Subject)

      11/14/24 5:08:44 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Eyenovia Inc.

      SC 13D/A - EYENOVIA, INC. (0001682639) (Subject)

      7/18/24 7:46:49 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant

      8-K - EYENOVIA, INC. (0001682639) (Filer)

      5/2/25 5:20:18 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - EYENOVIA, INC. (0001682639) (Filer)

      5/2/25 5:15:43 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Eyenovia Inc.

      10-K/A - EYENOVIA, INC. (0001682639) (Filer)

      4/30/25 4:05:54 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EYEN
    Financials

    Live finance-specific insights

    See more
    • Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update

      Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for interim analysis this quarter Commenced the manufacture of registration batches of Mydcombi in its second generation Optejet device Announced the U.S. launch and commercial availability of clobetasol propionate ophthalmic suspension 0.05% for the treatment of inflammation and pain following ocular surgery Appointed Andrew Jones as Chief Financial Officer Company to host conference call and webcast today, November 12th, at 4:30 pm ET NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic technology company developing and commercializing adv

      11/12/24 4:05:00 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th

      NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that the Company will release financial results for the third quarter ended September 30, 2024 on Tuesday, November 12th, 2024, after the markets close. Following the release, Eyenovia management will host a conference call and webcast at 4:30 p.m. ET to review the financial and operating results. Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) and reference Conference ID# 13748714. To access t

      11/7/24 7:00:00 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update

      Following FDA consultation, announced plans for validation of the Gen-2 Optejet® device and 2025 regulatory submission with Mydcombi™ as lead product Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for analysis in Q4 Commenced sales activities with focus on Mydcombi in 260+ offices and preparations for launch of clobetasol propionate ophthalmic suspension 0.05%, the first new ophthalmic steroid to enter the market in 15 years Announced development collaborations with Formosa, Senju and SGN to leverage the Optejet for the $5 billion global dry eye disease market Company to host conference call and webcast today, August 12th, a

      8/12/24 4:05:00 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EYEN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $EYEN
    Leadership Updates

    Live Leadership Updates

    See more

    $EYEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $EYEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • FDA Approval for MYDCOMBI issued to EYENOVIA INC.

      Submission status for EYENOVIA INC.'s drug MYDCOMBI (ORIG-1) with active ingredient TROPICAMIDE AND PHENYLEPHRINE HYDROCHLORIDE has changed to 'Approval' on 05/05/2023. Application Category: NDA, Application Number: 215352, Application Classification: Type 5 - New Formulation or New Manufacturer

      5/8/23 1:05:04 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer

      NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced the appointment of experienced finance and accounting executive Andrew Jones as Chief Financial Officer. Mr. Jones brings to the Eyenovia team more than 30 years of diverse finance and accounting leadership experience spanning therapeutics and medical technology/devices, most recently serving as Chief Financial Officer of NovaBay Pharmaceuticals, Inc., a publicly traded, commercial stage ophthalmic company. Eyenovia's current CFO, John Gandolfo, is retiring and will remain with

      9/3/24 7:00:00 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member

      NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced the appointment of current Chief Operating Officer Michael Rowe as the Company's new Chief Executive Officer, effective August 1, 2022. Mr. Rowe's appointment follows the company's nationwide search and interviews with multiple candidates. Mr. Rowe has also been appointed to Eyenovia's Board of Directors, increasing the Board to nine seats following recent appointments of Drs. Strahlman and Palanki as new independent directors, announced in July. Eyenovia's current Chief Exec

      7/27/22 8:00:00 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia Provides Manufacturing Update and Announces Appointment of Bren Kern as SVP of Manufacturing and Operations

      NEW YORK, July 18, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today provided an update on its expanded manufacturing capabilities and also announced the appointment of Bren Kern as Senior Vice President of Manufacturing and Operations. Redwood City, CA Facility The Company today announced that its new manufacturing facility in Redwood City, CA is operational. The facility, which is located in close proximity to Silicon Valley-based vendors and customers, will primarily focus on Optejet® manufacturing finishing operations, including drug loading, label

      7/18/22 8:00:00 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Strahlman Ellen R was granted 3,000 shares, increasing direct ownership by 176% to 4,706 units (SEC Form 4)

      4/A - EYENOVIA, INC. (0001682639) (Issuer)

      4/29/25 7:58:58 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Palanki Ram was granted 3,000 shares, increasing direct ownership by 243% to 4,235 units (SEC Form 4)

      4/A - EYENOVIA, INC. (0001682639) (Issuer)

      4/29/25 7:57:08 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Mather Charles E Iv was granted 8,000 shares, increasing direct ownership by 410% to 9,950 units (SEC Form 4)

      4/A - EYENOVIA, INC. (0001682639) (Issuer)

      4/29/25 7:56:40 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Rowe Michael M bought $14,077 worth of shares (27,071 units at $0.52), increasing direct ownership by 33% to 109,998 units (SEC Form 4)

      4 - EYENOVIA, INC. (0001682639) (Issuer)

      8/28/24 8:01:36 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Rowe Michael M bought $28,500 worth of shares (50,000 units at $0.57), increasing direct ownership by 152% to 82,927 units (SEC Form 4)

      4 - EYENOVIA, INC. (0001682639) (Issuer)

      8/27/24 1:06:37 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Grant Stuart M. bought $1,000,000 worth of shares (1,515,151 units at $0.66), increasing direct ownership by 16% to 10,914,153 units (SEC Form 4)

      4 - EYENOVIA, INC. (0001682639) (Issuer)

      7/3/24 3:18:06 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care